Engineering Placental Mesenchymal Stem Cells with PEDF for Retinal Protection in Diabetic Retinopathy

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Endocrinology

Background:

• Diabetic retinopathy (DR) is a leading cause of blindness.
• DR involves retinal vascular dysfunction and pathological angiogenesis.
• The balance between VEGF and PEDF is crucial in DR pathogenesis.

Purpose of the Study:

• To investigate the therapeutic potential of placenta-derived mesenchymal stem cells (PD-MSCs) in a rat model of diabetic retinopathy.
• To evaluate the efficacy of genetically engineered PD-MSCs overexpressing pigment epithelium-derived factor (PEDF) in treating DR.
• To analyze the modulation of VEGF and PEDF levels by PD-MSC transplantation in diabetic retinas.

Main Methods:

• A diabetic retinopathy model was established in rats using streptozotocin (STZ) injection.
• Naïve PD-MSCs or PEDF-overexpressing PD-MSCs (PD-MSCs^PEDF) were intravitreally transplanted.
• VEGF and PEDF expression levels were assessed in retinal tissues.

Main Results:

• PD-MSC transplantation reversed increased VEGF and decreased PEDF expression in diabetic retinas.
• PD-MSCs^PEDF treatment led to higher PEDF and lower VEGF levels compared to naïve PD-MSCs.
• These molecular changes were also observed in the contralateral non-transplanted eyes.

Conclusions:

• Engineering PD-MSCs^PEDF enhances their anti-angiogenic properties.
• PD-MSCs^PEDF effectively modulate the VEGF/PEDF balance.
• This approach alleviates vascular damage in STZ-induced diabetic retinopathy, offering a promising therapeutic strategy.